BioTech 365

APRIL 26, 2021

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology – ResearchAndMarkets.com United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & (..)

Generic Drugs 40

Generic Drugs Dermatology Hormones Marketing 40

Pharmaceutical Technology

SEPTEMBER 29, 2022

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Holding a presence in the cosmetic dermatology sector, Curatio’s portfolio comprises more than over 50 brands that are commercialised in India. The portfolio includes brands such as Tedibar, Atogla, Spoo, B4 Nappi and Permite.

Dermatology 147

Dermatology Cosmetics Branding Scientist 147

BioPharma Reporter

NOVEMBER 21, 2023

A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.

Medicine 97

Medicine Dermatology Drugs Regulation 97

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. In Canada, access to dermatological care is extremely limited, with only 1.7 In Canada, access to dermatological care is extremely limited, with only 1.7

Dermatology 130

Dermatology Pharmacy Branding Marketing 130

Pharmaceutical Technology

APRIL 19, 2023

Arcutis Biotherapeutics president and CEO Frank Watanabe stated: “The acceptance of the NDA for roflumilast foam marks a major milestone toward our goal of bringing a steroid-free, topical foam treatment option to market, addressing a significant unmet need for individuals living with seborrheic dermatitis. “If

Dermatology 130

Dermatology Trials Drugs Regulation 130

Outsourcing Pharma

DECEMBER 13, 2021

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

Cardiology 145

Cardiology Dermatology Development Regulation 145

Pharmaceutical Technology

MAY 19, 2023

The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. Rinvoq is a major pillar in AbbVie’s plan to stem revenue drops once biosimilars to its behemoth Humira (adalimumab) enter the market on a sustained basis this year.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

pharmaphorum

APRIL 29, 2022

The tool has been used to assess more than 23,000 patients and discover almost 1,500 cases of cancer, whilst reducing the number if dermatology appointments needed by more than 4,700, said the company.

Dermatology 145

Dermatology Containment Marketing Development 145

BioPharma Reporter

JANUARY 23, 2024

Dermatology biopharma company Arcutis has launched ZORYVE, a topical foam for the treatment of seborrheic dermatitis, in the United States for individuals 9 years of age and older.

Dermatology 52

Dermatology Regulation Marketing 52

XTalks

APRIL 17, 2023

These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release. percent to be worth $26.5 billion by 2028.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy. These drugs are set to make a combined $4.34bn in sales in 2028.

Drugs 264

Drugs Sales Antibody Dermatology 264

Pharmaceutical Technology

MARCH 27, 2023

Thus, positive outcomes for these gene therapies including those in early-stage development targeting VEGF may instigate changes in the marketed landscape, resulting in diversified targets within the drug market across therapy areas such as oncology and CNS. However, gene therapies remain key molecule types for these targets.

Medicine 246

Medicine Gene Therapy Gene Dermatology 246

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. About the interviewee. Dr. Thyssen, MD, Ph.D.

Dermatology 100

Dermatology Trials Drugs Development 100

pharmaphorum

NOVEMBER 9, 2021

However, the rise in research and development has created a crowded market that healthcare professionals struggle to navigate. Market access advice for launching in crowded landscapes. Market access advice for launching in crowded landscapes. The landscape is booming with treatment innovations. DOWNLOAD THE FULL EBOOK HERE.

Life Science 52

Life Science Marketing Development Research 52

pharmaphorum

FEBRUARY 3, 2021

For the last three years he has served as executive vice president, growth markets commercial, at Israeli pharma Teva. Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month. Gianfranco Nazzi.

Dermatology 52

Dermatology Marketing Branding Medicine 52

Pharmaceutical Technology

DECEMBER 5, 2022

Incyte has signed a partnership and licence agreement with CMS subsidiary CMS Aesthetics to develop and market ruxolitinib cream to treat autoimmune and inflammatory dermatologic ailments in Greater China and some Southeast Asian countries.

Dermatology 130

Dermatology FDA Approval Sales Production 130

pharmaphorum

SEPTEMBER 15, 2022

” The Swiss Competition Commission (COMCO) arrived unexpectedly at Novartis at dawn on Tuesday morning, to gather information on an unidentified dermatology drug, as part of a wider investigation into the drugmaker by the European Commission.

Dermatology 118

Dermatology Production Pharma Companies Marketing 118

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

pharmaphorum

APRIL 28, 2021

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested. . The post Crowded psoriasis market cuts Lilly’s mirikizumab ambitions appeared first on. Johnson & Johnson’s $7.7

Marketing 52

Marketing Trials Drugs Antibody 52

pharmaphorum

AUGUST 17, 2022

At Fishawack Health (FH), we are committed to investing in the field of dermatology. In November 2022, we welcomed FIDE , an independent network of expert partners in dermatology, to inform industry specialists as to the potential impact of the latest data and how it may affect their strategic decision-making.

Dermatology 52

Dermatology Development Sales Marketing 52

The Pharma Data

JUNE 2, 2023

Zouboulis, President of the European Hidradenitis Suppurativa Foundation, Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at the Brandenburg Medical School, Germany.

Dermatology 52

Dermatology Medicine Production Marketing 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharma in Brief

JANUARY 15, 2024

2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders. Galderma ), markets two adapalene products in Canada: Differin ® , which contains 0.1% concentration of adapalene for the treatment of dermatological disorders. The FC concluded that the Board’s decision was reasonable.

Dermatology 52

Dermatology Medicine Containment Production 52

BioTech 365

OCTOBER 27, 2020

NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2020 financial results after the market closes on … Continue reading → .–(BUSINESS WIRE)–DermTech, Inc.

Dermatology 40

Dermatology Genome Genomics Marketing 40

STAT News

DECEMBER 2, 2022

And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Dermatology 98

Drug Discovery World

MARCH 13, 2024

“Data from the FRONTIER 2 study showed that the skin clearance as seen by PASI 75 and higher-bar PASI 90 and 100 responses at 16 weeks was maintained at 52 weeks with no new safety signals across all JNJ-2113 treatment groups,” said Dr Laura Ferris, Professor of Dermatology, University of Pittsburgh.

Trials 52

Trials Dermatology Clinical Trials Clinical Trials 52

pharmaphorum

DECEMBER 29, 2021

The green light comes later than Leo hoped, as the FDA turned down the dermatology specialist’s first attempt last year, despite making it through regulatory reviews in the EU, UK, Canada and UAE where it is already launched as Adtralza. Leo now says it will start rolling the new product out in February. billion in the same year.

Sales 111

Sales Dermatology Marketing Allergies 111

Pharma Marketing Network

MAY 11, 2021

She has helped to launch, grow and evolve brands & portfolios across many categories, including Oncology, Neurology, Dermatology, Diabetes, Orthopedics, Respiratory and Virology. The post Carol Patel appeared first on Pharma Marketing Network.

Dermatology 52

Dermatology Branding Marketing Development 52

Delveinsight

SEPTEMBER 28, 2021

Innovent, UNION Therapeutics Set to Advance Dermatology Market in China. Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast , a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Dermatology 80

XTalks

MARCH 6, 2023

The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. The US has always been an important market for us,” said Chief Executive Officer of Dr. Reddy’s, Erez Israeli, in a statement.

Production 98

Production Branding Dermatology Hormones 98

XTalks

MARCH 24, 2023

The company recently presented a pooled analysis from clinical studies of their DermaSensor skin cancer detection device at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The global skin cancer diagnostics market is anticipated to reach $5.48 billion by 2028 from $3.36 percent, according to The Insight Partners.

Dermatology 97

Dermatology Clinical Trials Clinical Trials Sales 97

pharmaphorum

AUGUST 28, 2020

Shares in dermatology specialist Cassiopea, which is listed on the SWX exchange in Switzerland, rose almost 17% after news of the FDA approval emerged. The biotech isn’t revealing how much it intends to charge for the new medicine, saying it will do so closer to launch later this year.

Dermatology 52

Dermatology Drugs Hormones FDA Approval 52